A股異動 | 瑞普生物(300119.SZ)漲約4% 取得獸藥產品批准文號 涉及副豬嗜血桿菌病三價滅活疫苗
格隆匯12月15日丨瑞普生物(300119.SZ)漲約4%,報23.77元,總市值111億元。瑞普生髮布公吿,公司空港經濟區分公司近日獲得了由農業農村部核發的“副豬嗜血桿菌病三價滅活疫苗(4型H4L1株+5型H5L3株+12型H12L3株)”獸藥產品批准文號。該產品的研製成功,推動了公司產品的升級、豐富了公司豬類細菌疫苗產品結構,有助於提升公司服務我國養豬業的能力,提高我國豬病防控水平,進而減少抗生素使用量。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.